174 related articles for article (PubMed ID: 31490070)
21. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG
Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.
Jiang W; Hou Q; Xu H; Yang K; Wang X; Zhang K; Zeng Y; Li W; Wang B; Luo G; Zhao X; Shen H; Xu Y; Wu X
J Med Chem; 2024 Jan; 67(2):1513-1532. PubMed ID: 38175809
[TBL] [Abstract][Full Text] [Related]
23. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
24. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
Certal V; Carry JC; Halley F; Virone-Oddos A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Karlsson A; Charrier V; Delorme C; Rak A; Abecassis PY; Amara C; Vincent L; Bonnevaux H; Nicolas JP; Mathieu M; Bertrand T; Marquette JP; Michot N; Benard T; Perrin MA; Lemaitre O; Guerif S; Perron S; Monget S; Gruss-Leleu F; Doerflinger G; Guizani H; Brollo M; Delbarre L; Bertin L; Richepin P; Loyau V; Garcia-Echeverria C; Lengauer C; Schio L
J Med Chem; 2014 Feb; 57(3):903-20. PubMed ID: 24387221
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Ali I; Lee J; Go A; Choi G; Lee K
Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
27. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
[TBL] [Abstract][Full Text] [Related]
28. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
Hu J; Wang Y; Li Y; Cao D; Xu L; Song S; Damaneh MS; Li J; Chen Y; Wang X; Chen L; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2018 Apr; 150():156-175. PubMed ID: 29525435
[TBL] [Abstract][Full Text] [Related]
29. Design and Synthesis of a Highly Selective and
Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
[TBL] [Abstract][Full Text] [Related]
31. Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1
Lv K; Chen W; Chen D; Mou J; Zhang H; Fan T; Li Y; Cao D; Wang X; Chen L; Shen J; Pei D; Xiong B
J Med Chem; 2020 Sep; 63(17):9787-9802. PubMed ID: 32787081
[TBL] [Abstract][Full Text] [Related]
32. Discovery of BET specific bromodomain inhibitors with a novel scaffold.
Pandit N; Yoo M; Hyun Park T; Kim J; Mi Kim S; Myung Lee K; Kim Y; Min Bong S; Il Lee B; Jung KY; Hoon Park C
Bioorg Med Chem; 2022 Oct; 72():116967. PubMed ID: 36099719
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
35. Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
Fidanze SD; Liu D; Mantei RA; Hasvold LA; Pratt JK; Sheppard GS; Wang L; Holms JH; Dai Y; Aguirre A; Bogdan A; Dietrich JD; Marjanovic J; Park CH; Hutchins CW; Lin X; Bui MH; Huang X; Wilcox D; Li L; Wang R; Kovar P; Magoc TJ; Rajaraman G; Albert DH; Shen Y; Kati WM; McDaniel KF
Bioorg Med Chem Lett; 2018 Jun; 28(10):1804-1810. PubMed ID: 29678460
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Discovery and Optimization of Furo[3,2-
Li J; Zhang C; Xu H; Wang C; Dong R; Shen H; Zhuang X; Chen X; Li Q; Lu J; Zhang M; Wu X; Loomes KM; Zhou Y; Zhang Y; Liu J; Xu Y
J Med Chem; 2022 Apr; 65(7):5760-5799. PubMed ID: 35333526
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
[TBL] [Abstract][Full Text] [Related]
38. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Imamura K; Tomita N; Kawakita Y; Ito Y; Ono K; Nii N; Miyazaki T; Yonemori K; Tawada M; Sumi H; Satoh Y; Yamamoto Y; Miyahisa I; Sasaki M; Satomi Y; Hirayama M; Nishigaki R; Maezaki H
Bioorg Med Chem; 2017 Jul; 25(14):3768-3779. PubMed ID: 28571972
[TBL] [Abstract][Full Text] [Related]
40. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
